Following some preliminary meetings with Health Innovation Manchester
(a multi-stakeholder organisation that works with innovators to
discover, develop and deploy new solutions that improve the health and
wellbeing of its citizens), it became clear than the ethos and
ambitions of Cities Changing Diabetes aligned with those of the city,
especially in its desire to tackle urban diabetes through innovate means.
As a result of the recent devolution of healthcare budget in Greater
Manchester, and the creation of The Health & Social Care
Partnership, the city is on its way to becoming one of the first
joined up health innovation system in the world.
The focus on research, prevention, management and elimination of
type 2 diabetes has been central to the production of the Greater
Manchester (GM) strategy for tackling diabetes, which has been devised
within the context of the GM Population Health Plan, its focus on
lifestyle approaches to health and its aims to improve the
utilisation of personal health budgets and social prescribing.
Greater Manchester’s vision is to improve the lives of all people
across GM affected by diabetes and at risk of developing it and have
recognised clear benefits in embracing this opportunity with Novo
Nordisk. The Cities Changing Diabetes partnership will not only
highlight Greater Manchester’s existing work on a global platform but
also present many exciting opportunities to work collaboratively with
other partners around the world to map, share and act.
“We are delighted to have joined the global Cities Changing
Diabetes programme and we are looking forward to developing new
innovations and research within our system to deliver diabetes
prevention and treatment with a person-centred approach within
— Dr Tracey Vell, clinical director of Health Innovation Manchester
Manchester fact sheet